One note a week, every Sunday. Provider-written — not a marketing team. Citations where citations belong; honest where they don’t. About sixty percent of our roster reads them; the other forty percent is too busy living their lives.
Industry-standard dosing creeps to 36–48. A note on movement preservation, two-week reassessment, and why we'd rather see you back at week 13.
When a treatment isn't safe at standard fluence, the answer isn't to lower the fluence; it's to use a different device. A practical guide.
We use cannulas for tear-trough, jawline, and most cheek work. We don't use them for lip. The reasoning, illustrated with anatomy diagrams.
The math on combining tirzepatide with Emsculpt Neo. When the protocol overlaps, when it competes, what to expect at month four.
Practices that lead with pricing tend to over-treat. A note on consultation-led care, the 30-minute visit, and what we leave on the table.
About 1 in 25 of our consults is a patient asking us to dissolve work done elsewhere. The protocol, the pricing, the rationale.
